eligibility_summary
Adults (≥18) with advanced solid tumors lacking SOC options, ECOG ≤2, life expectancy ≥3 mo, measurable disease (RECIST) for Ph1b/2, FFPE tumor tissue available, adequate marrow/renal/hepatic/coagulation, effective contraception, prior ADCs allowed, but no prior MMAE in Ph1b/2. Exclude: ≥Grade2 neuropathy, uncontrolled CNS mets, ≤14d investigational/anticancer drugs/CYP3A strong meds/VTE/bleeding, recent major surgery, serious cardiac or QTcF>470, active HIV/hepatitis/infection, recent other cancers, ocular disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: MBRC-101, an antibody-drug conjugate (ADC). Type/mechanism: a human anti‑EphA5 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a potent antimitotic chemotherapeutic. Mechanism of action: MBRC-101 binds the EphA5 receptor on tumor cells, is internalized, and releases MMAE intracellularly to inhibit tubulin polymerization, inducing G2/M arrest and apoptosis. Targets: EphA5 (an Eph receptor tyrosine kinase) on advanced solid tumors, pathway focus is the Eph/ephrin signaling axis (implicated in tumor growth, invasion, and survival) and microtubule dynamics via MMAE. Tumor contexts under study include NSCLC, breast (TNBC, HR+/HER2−), pancreatic, gastric, hepatocellular, ovarian, and multiple squamous cell carcinomas.